At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Viking Therapeutics (VKTX) surges 10% on renewed takeover speculation, with Pfizer rumored as a potential buyer.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...

As obesity rates rise, eligibility expands and curiosity about these medications grows ... a triple-hormone-receptor agonist combining GLP-1, GIP and glucagon receptors. Early trial data published ...

Feb. 12, 2024 – People with type 2 diabetes taking GLP-1 medicines may experience potentially blinding eye conditions as soon as the day after starting the drugs, and eye doctors are now asking ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

This medication also mimics GLP-1, in addition to ... polypeptide (or GIP), which plays a role in fat metabolism. Beyond treating type 2 diabetes and obesity, GLP-1 drugs are showing surprising ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...